Editas Medicine Inc（EDIT）财务数据EDITEditas Medicine Inc

Evaluating the bottom line, Editas Medicine, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -167.31%, while the net margin is -153.32%. These profitability ratios, combined with a Return on Equity (ROE) of -118.82%, provide a clear picture of how effectively EDIT converts its operational activities into shareholder value.

In the context of the broader market, EDIT competes directly with industry leaders such as PRTA and VOGX. With a market capitalization of $433.10M, it holds a significant position in the sector. When comparing efficiency, EDIT's gross margin of 100.00% stands against PRTA's 100.00% and VOGX's N/A. Such benchmarking helps identify whether Editas Medicine, Inc. is trading at a premium or discount relative to its financial performance.

Editas Medicine reported a narrower net loss of $18.23 million for Q2 2026, a significant improvement from the previous year's loss of $53.23 million. Revenue for Q2 2026 was $11.89 million, up from $3.58 million a year earlier, indicating positive growth in R&D revenue.